For the drugs in other categories: (1) acalabrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor on the B-cell receptor signaling pathway that communicates with other immune cells and results in B-cell proliferation and activation [62] and (2) dapagliflozin is a sodium–glucose cotransporter 2 inhibitor used as the antihyperglycemic treatment for diabetes. Here, BTK is linked to diabetes mellitus.